BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allegra S, De Francia S, Cusato J, Pirro E, Massano D, Piga A, D'Avolio A. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. J Pharm Pharmacol 2016;68:1417-21. [PMID: 27672004 DOI: 10.1111/jphp.12638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao K, Ren G, Lu C, Wang Y, Tan Y, Zhou J, Zhang Y, Lu Y, Li N, Chen X, Zhao D. ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects. Eur J Clin Pharmacol 2020;76:51-9. [DOI: 10.1007/s00228-019-02775-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lima TGD, Benevides FLN, Esmeraldo Filho FL, Farias IS, Dourado DXC, Fontenele EGP, Moraes MEAD, Quidute ARP. Treatment of iron overload syndrome: a general review. Rev Assoc Med Bras 2019;65:1216-22. [DOI: 10.1590/1806-9282.65.9.1216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Gray JP, Suhali-amacher N, Ray SD. Metals and Metal Antagonists. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Elsevier; 2017. pp. 197-208. [DOI: 10.1016/bs.seda.2017.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Avataneo V, De Nicolò A, Piga A, D'Avolio A. The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. Pharmacogenomics J 2019;19:417-27. [PMID: 30651574 DOI: 10.1038/s41397-019-0071-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Avataneo V, De Nicolò A, Piga A, D'Avolio A. Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. Pharmacogenet Genomics 2018;28:199-206. [PMID: 30179981 DOI: 10.1097/FPC.0000000000000348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, Islampanah M, Naghsh N, Abbasalizadeh M, Deravi N, Abd Elhakim Y. Iron Chelators in Treatment of Iron Overload. Journal of Toxicology 2022;2022:1-18. [DOI: 10.1155/2022/4911205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hamed EM, Meabed MH, Hussein RRS, Aly UF. Recent insight on improving the iron chelation efficacy of deferasirox by adjuvant therapy in transfusion dependent beta thalassemia children with sluggish response. Expert Opin Drug Metab Toxicol 2020;16:179-93. [PMID: 32067512 DOI: 10.1080/17425255.2020.1729353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]